Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synovis Life Technologies, Inc. (“Synovis” or the “Company”) (Nasdaq: SYNO) relating to the proposed acquisition by Baxter International, Inc. (“Baxter”) (NYSE: BAX). Under the terms of the transaction, Synovis shareholders would receive $28.00 in cash for each share of Synovis common stock they own. The transaction has a total approximate value of $325 million. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Synovis for not acting in Synovis shareholders' best interests in connection with the sale process to Baxter. If you own shares of Synovis and wish to discuss the legal ramifications of the proposed transaction, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at firstname.lastname@example.org, visiting http://brodsky-smith.com/369-syno-synovis-life-technologies-inc.html, or by calling toll free 877-LEGAL-90.
Synovis Life Technologies (Nasdaq:SYNO) hit a new 52-week high Tuesday as it is currently trading at $28.01, above its previous 52-week high of $28 with 31,366 shares traded as of 1:32 p.m. ET. Average volume has been 165,800 shares over the past 30 days.
Synovis Life Technologies (Nasdaq:SYNO) hit a new 52-week high Tuesday as it is currently trading at $27.98, above its previous 52-week high of $27.97 with 52,394 shares traded as of 3 p.m. ET. Average volume has been 165,800 shares over the past 30 days.
Shares of Synovis Life Technologies (Nasdaq:SYNO) were gapping up Tuesday morning with an open price 50.5% higher than Monday's closing price. The stock closed at $18.44 yesterday and opened today's trading at $27.75.